The combination of 5-FU (fluorouracil) and Kenalog (triamcinolone) works for hypertrophic acne scars because it attacks the problem from two complementary angles: 5-FU suppresses the overactive fibroblasts that create excess collagen buildup, while Kenalog reduces inflammation and prevents new scar tissue formation. When injected directly into raised scars, this pairing addresses the root cause of hypertrophic scarring—the skin’s excessive healing response—rather than just smoothing the surface.
For someone with prominent raised scars from severe acne, a series of these combination injections can flatten scars by 40-60% over several months, something topical treatments alone cannot achieve. This article explains how this two-drug approach works at a cellular level, why it’s particularly effective for the specific type of scarring it targets, what results you can realistically expect, and how it compares to other professional scar treatments. We’ll also cover the limitations of this approach, because while effective, it doesn’t work equally well for all scar types or all patients.
Table of Contents
- How Do 5-FU and Kenalog Target Hypertrophic Scars Differently?
- Why This Combination Works Better Than Either Drug Alone
- What Types of Acne Scars Respond Best to This Treatment?
- Treatment Protocol and What to Expect During the Process
- Limitations and When the Combination Doesn’t Work
- How This Compares to Other Professional Scar Treatments
- Future Directions and Emerging Research
- Conclusion
How Do 5-FU and Kenalog Target Hypertrophic Scars Differently?
Hypertrophic scars form when the body’s healing response goes into overdrive, producing more collagen than needed to repair acne damage. Fibroblasts—the cells responsible for making collagen—become hyperactive and stay that way, causing the scar tissue to build up above the surrounding skin. Kenalog works first by suppressing these fibroblasts directly through its corticosteroid action, essentially telling the cells to stop producing excess collagen. At the same time, the corticosteroid reduces the inflammatory signals that keep fibroblasts activated, creating a double brake on scar progression.
5-FU takes a different path. It’s a chemotherapy agent that damages fibroblast DNA, effectively killing a portion of these overactive cells or forcing them into dormancy. When used at the low doses appropriate for dermatology, 5-FU doesn’t cause systemic toxicity but does accumulate in scarred tissue where it preferentially affects rapidly dividing fibroblasts. The combination works because Kenalog immediately dampens the inflammatory environment while 5-FU eliminates the cells that would otherwise replenish the problem. A dermatologist might inject this combination into a chest or shoulder scar—common sites for hypertrophic acne scars—and see progressive flattening over 3-4 treatment sessions spaced 4-6 weeks apart.
Why This Combination Works Better Than Either Drug Alone
Neither drug works optimally in isolation for hypertrophic scarring. Kenalog alone can flatten scars, but the effect is often temporary; once you stop injecting, fibroblasts may reactivate and scars can re-elevate over months. 5-FU alone has more durable effects on fibroblast numbers, but without Kenalog’s anti-inflammatory component, patients experience more injection site swelling, pain, and risk of hyperpigmentation during the healing phase.
By combining them, clinicians get the immediate anti-inflammatory benefit of Kenalog plus the longer-term fibroblast reduction from 5-FU, producing results that last longer and with fewer side effects than either could achieve independently. However, if a patient has extensive hypertrophic scars across a large body surface area—say, severe acne scarring on the entire back—multiple treatment sessions become expensive and logistically demanding. Some dermatologists might choose to start with Kenalog injections alone in such cases to assess the patient’s response before committing to a multi-session 5-FU combination protocol. Additionally, if a scar is actively inflamed or infected, any injection is contraindicated until the acute inflammation resolves, which can delay treatment by weeks.
What Types of Acne Scars Respond Best to This Treatment?
The 5-FU and Kenalog combination is most effective for true hypertrophic scars—raised, thickened scars that stay within the original wound boundary. These often have a firm, rubbery texture and are most common on the chest, shoulders, and upper back where skin tension is highest. A patient with a prominent raised scar from a cystic acne lesion is an ideal candidate. The raised appearance typically improves within 2-3 weeks of the first injection, with continued improvement through the course of treatment.
Atrophic scars—the depressed, pitted scars that make up the majority of acne scarring—respond poorly to this combination because the problem isn’t excessive collagen but rather missing collagen. These scars need resurfacing treatments like laser, microneedling, or chemical peels, not fibroblast suppression. Similarly, ice-pick scars (narrow, deep indentations) rarely respond well to injections alone. A dermatologist evaluating a patient with mixed scarring—some raised, some depressed—might use the 5-FU/Kenalog combination on the hypertrophic components while planning separate treatments for atrophic scars.
Treatment Protocol and What to Expect During the Process
The typical treatment protocol involves injecting the 5-FU and Kenalog combination directly into the scar tissue using a fine needle, usually with a concentration of 0.5 mg/mL 5-FU mixed with 10 mg/mL Kenalog. The volume injected per site is small—usually 0.1-0.2 mL per injection—to avoid excessive swelling. Patients return for repeat sessions every 4-6 weeks, typically for 3-4 sessions, though severe scars may require more. The injection itself causes minor discomfort but is tolerable for most people; many dermatologists apply topical numbing cream beforehand.
Immediately after injection, patients experience localized swelling and mild erythema (redness), which can take 24-48 hours to fully resolve. Some patients report burning or stinging at the injection site for a few hours post-treatment. The actual scar flattening becomes noticeable within 2-3 weeks as inflammation subsides and fibroblasts respond to the drugs, though the most dramatic improvements appear over 8-12 weeks. In contrast, laser scar revision produces visible results within days but requires longer recovery time with peeling and redness, making the injection approach less conspicuous for patients who can’t tolerate downtime. Cost-wise, each 5-FU/Kenalog injection session typically ranges from $300-800 depending on the number of scars treated, while a full course of 3-4 sessions might cost $1000-3000 total—considerably less than ablative laser treatment.
Limitations and When the Combination Doesn’t Work
Not all patients respond equally to this treatment. Some individuals are poor responders—their hypertrophic scars flatten only minimally despite the full course of injections, likely due to genetic differences in fibroblast behavior or underlying collagen deposition patterns. Darker skin types sometimes experience post-inflammatory hyperpigmentation or, rarely, hypopigmentation at injection sites, which can be more noticeable than the original scar in some cases. If this occurs, it typically fades over months but can be psychologically distressing; it’s a risk that must be discussed before treatment in patients with darker skin.
Additionally, the combination carries a small risk of scar atrophy if too much volume is injected or if the drugs diffuse beyond the intended scar tissue into normal surrounding skin. This can create a depression at the injection site that’s actually worse than the original raised scar. Dermatologists mitigate this by using small injection volumes and precise placement, but the risk remains real. Pregnancy is a contraindication because the effects of 5-FU on a developing fetus are unknown; women of childbearing age should use reliable contraception during treatment and for some time afterward, though data on exact duration of concern is limited.
How This Compares to Other Professional Scar Treatments
Other professional treatments for hypertrophic scars include ablative lasers (CO2 or erbium), non-ablative lasers, microneedling with radiofrequency, and subcision. Ablative lasers vaporize the upper layers of scar tissue and stimulate collagen remodeling, producing faster visible results—often within a single session—but require 2-3 weeks of peeling and redness. The 5-FU/Kenalog combination is less dramatic but requires no downtime and involves minimal visibility of treatment. For a professional who cannot afford significant redness or peeling, injections are preferable.
However, ablative lasers often produce superior flattening of severe hypertrophic scars in a single session compared to the gradual improvement from injections. Microneedling is less invasive than laser and works well for mild to moderate scars, but for thick, fibrotic hypertrophic tissue, it’s often less effective than either injections or laser. Subcision—surgically breaking up scar tissue beneath the skin—can be combined with injections for even better results, though it adds cost and invasiveness. Some dermatologists use a sequential approach: starting with 5-FU/Kenalog injections for 3-4 months, then following with laser if residual scarring remains.
Future Directions and Emerging Research
Ongoing research is exploring whether adding other agents to the 5-FU/Kenalog combination could improve results further. Some dermatologists are experimenting with adding bleomycin, another chemotherapy agent, or combining injections with laser or microneedling in the same session for synergistic effect. Early data suggests these combinations may produce faster or more complete scar improvement, though larger clinical trials are needed.
Additionally, researchers are investigating whether timing matters—whether injecting during the scar’s earlier remodeling phase (within the first year of scar formation) produces better results than treating older, more established scars. Preliminary evidence suggests treating scars within the first 6-12 months yields better outcomes, which has implications for when acne patients should seek treatment. The development of topical fibroblast-suppressing agents that could achieve some of the benefits of injection without the invasiveness remains an active area of research, though nothing currently available is clinically comparable to injected 5-FU.
Conclusion
The 5-FU and Kenalog combination works for hypertrophic acne scars by simultaneously suppressing inflammatory signals (Kenalog) and reducing the fibroblast population responsible for excessive collagen production (5-FU), producing progressive scar flattening over 3-4 treatment sessions. This approach is most appropriate for raised, thickened scars rather than depressed or atrophic scars, and works best on patients with ideal skin types and realistic expectations about gradual improvement.
If you have hypertrophic acne scars and are considering this treatment, schedule a consultation with a dermatologist experienced in intralesional injection therapy. They can evaluate whether your scars are appropriate for this approach, discuss realistic improvement expectations based on your specific scar characteristics, and review the risk profile for your skin type. While not every hypertrophic scar responds perfectly, many patients achieve meaningful cosmetic improvement that justifies the modest time and financial investment.
